Amgen Inc. shares ticked up slightly in the extended session Thursday after the biotech company said the Food and Drug Administration approved its new cholesterol treatment. Amgen shares rose 0.5% to $156.56. The company said the treatment, Repatha, lowers “bad” cholesterol by blocking a protein that reduces the liver’s ability to remove it from the blood.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News